Three in four biopharma professionals say geopolitical and trade uncertainty is changing their supply-chain strategy, and 78% say it is changing how they outsource. Those figures come from BIO-Europe’s Globalization Reimagined survey, released by Informa Connect on November 2.
The sample is modest, at 139 respondents, weighted toward North America and Europe, yet it aligns with what GlobalData, the WTO, and a recent BioPharm International expert panel describe. The industry is redesigning globalization instead of abandoning it, diversifying suppliers and geographies while tightening due diligence on partners.
For anyone running multilingual content operations in life sciences, that shift carries a workload the survey never mentions. Every second-source CDMO, new API supplier, or newly opened market arrives with tech transfer packages, site master files, SOPs, batch records, quality agreements, labels, and variation filings. Most of those documents must exist in a language the receiving site can work from before any product moves. As a result, a diversified supply chain moves only as fast as the slowest document it needs in a new language, and it stays only as secure as the least governed tool that touches that document.
| Why is supply chain diversification increasing translation demand in biopharma? As pharmaceutical companies add suppliers, CDMOs, manufacturing sites, and markets, they must translate SOPs, quality agreements, labels, batch records, regulatory submissions, and patient-facing content into local languages. This makes multilingual document readiness, AI governance, and language quality assurance critical components of supply chain resilience. |
Why does supply chain diversification increase translation requirements?
The regulatory basis is unambiguous. EU GMP Chapter 4 requires document language to suit its intended use, which in practice means operators work from SOPs they understand. FDA expects a complete and accurate English translation of every non-English part of a drug application and can refuse to file without one. Meanwhile, the EU Clinical Trials Regulation requires lay summaries in the local languages of every trial country, so a single Belgian site triggers Dutch, French and German. Adding a supplier in a new country therefore becomes a translation project well before it becomes a production project.
The volume behind this is substantial. Large pharma has pledged more than USD 370 billion in US investment over five years, with Pfizer, AstraZeneca, Roche, Novartis and Johnson & Johnson all announcing commitments in 2025. Europe, for its part, has written supply-source diversity into public procurement for roughly 300 critical medicines, and the EU-India trade agreement, expected to take effect in early 2027, removes tariffs of up to 11% on pharmaceuticals. Some skepticism is fair, since Pharma Manufacturing has questioned how much of the US money firms would have spent anyway. Even so, multi-year rolling tech transfers make translation demand continuous and site-driven, so localization managers should plan around the CDMO onboarding calendar instead of the content calendar.
Which language pairs pose the greatest AI translation risk?
Here is the finding that deserves more attention. In July 2025, a JAMA Pediatrics study found GPT-4o Spanish translations of patient instructions comparable to professional work. Two months later, a JAMA Network Open study found AI-translated pediatric discharge instructions held up in Spanish but performed worse in Chinese, Somali, and Vietnamese. At the same time, Nimdzi reports that trade realignment is opening Asia-Pacific routes and creating demand for pairs such as Chinese into Indonesian, Japanese, or Korean.
Taken together, these findings point somewhere uncomfortable. Diversification pushes volume toward precisely the language pairs where AI performance is least proven, and an automation policy averaged across all languages will conceal that gap. Nimdzi has already documented buyers who ran raw AI on content once marked “not for MT,” suffered quality failures and hallucinations, and then returned to expert-in-the-loop providers.
For AI quality specialists, the practical response is evaluation stratified by language pair and content risk class, with tighter MQM sampling wherever models are weaker.
Similarly, prompt engineers will need richer context, jurisdiction-specific terminology injection, and firmer constraints for low-resource pairs. Curated in-domain data for those pairs is quickly becoming one of the few multilingual data assets that genuinely differentiates.
Your language partner is now part of the attack surface
Verizon’s 2026 Data Breach Investigations Report puts third-party involvement at 48% of breaches, up 60% in a single year. IBM’s 2026 Cost of a Data Breach study, which recorded a record global average cost of USD 4.99 million, also found that 53% of breached organizations had not encrypted sensitive data at rest or in transit.
This is worth further thought because a language supplier, its freelancers, and its AI subprocessors can handle unreleased specifications, clinical data, and process IP across several countries. The US BIOSECURE Act, with its first “companies of concern” list due by December 18, does not cover translation services, and analysts expect no enforceable prohibitions before late 2027. Nevertheless, it normalizes the question of which vendors sit behind your vendors.
Procurement teams will increasingly ask language partners who touched a file, where it was stored, which model processed it, and what that model retained.
How can generative AI create GMP compliance risks?
Secondary coverage of IBM’s study reports shadow AI incidents at 43% of breached organizations, up from 20% a year earlier. In regulated content, the consequences double because a translated SOP produced by an unapproved chatbot both leaks data and escapes document control.
FDA made that second risk concrete in April with its first warning letter citing overreliance on AI for cGMP documentation. The recipient had used AI agents to generate specifications, procedures, and master production records without Quality Unit review, and staff said they missed a validation requirement because the AI never flagged it.
The manufacturer is small and homeopathic, which is exactly why the case is significant. In a diversified network, small and newly onboarded suppliers are the most likely places for unreviewed AI output to surface. Draft EU GMP Annex 22 keeps generative AI out of critical GMP applications altogether, yet rules on paper rarely beat a deadline. Localization leaders therefore need a sanctioned route that is faster than the consumer alternative, with prompts and model versions under change control like any validated configuration.
The human in the loop gets tired
Human review is the standard answer, and regulators endorse it. However, a Danish Medicines Agency team told ISPE that reviewers become less vigilant when AI output is usually right, precisely when rare errors slip through. That warning lands on an industry already stretched thin.
Nimdzi reports that top 100 LSP revenue per employee rose 73.6% in 2025, experienced linguists are leaving post-editing work, and some buyers expect AI to cut costs by up to 75%. As a result, fewer senior reviewers now cover more output. Translation QA leads should design review to resist complacency, using seeded errors, sampling that rises for weaker pairs, and evidence packs that record reviewer identity, tool, model version, and error typology.
A regulator has already drawn the map
Interestingly, the clearest operating model comes from EMA (European Medicines Agency). Its language policy, updated in June, keeps technical content in English to limit errors translation can introduce, translates patient-relevant information into all official EU languages, and offers machine translation of general web pages with a quality disclaimer. In effect, a regulator has tiered translation by audience and risk. That model will face pressure soon, as the EU pharma package moves product information toward structured electronic formats around 2028 and turns labeling into continuously updated multilingual data.
BIO-Europe’s survey also found that 89% of respondents still see opportunity in the shifting landscape. Content readiness will help decide which of them capture it. The open question is whether localization joins supply-chain qualification before the deals signed in Cologne become tech transfers, or only after the first audit finding.
—
Key Takeaways
- Supply chain diversification increases multilingual documentation requirements.
- AI translation performance varies significantly between language pairs.
- Language providers must be evaluated as part of third-party risk management.
- Unapproved AI tools can create both privacy and GMP compliance issues.
- Document readiness should be treated as a supply chain capability, not a localization task.

